Ornipressin
Based on 1 Customer Validation
Ornipressin (POR-8) is a vasopressin agonist specific for the V1 receptor. Ornipressin can be used as a local vasoconstrictor. Ornipressin can reverse the hypotension associated with combine general/epidural anesthesia. Ornipressin has antidiuretic activity. Ornipressin decreases renal vascular resistance and increases renal blood flow in renal failure model.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.87%
- CAS. Nr.: 3397-23-7
- Formel: C45H63N13O12S2
- Molecular Weight:1042.19
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Macrocyclic Compound Library
HY-L041
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-COVID-19 Compound Library
HY-L052
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Peptide Library
HY-L105
-
Cyclic Peptide Library
HY-L110
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Activators Library
HY-L159
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Peptide Compound Library
HY-L105S
-
Bioactive Compound Library
HY-L001
-
Non-natural Amino Acid Compound Library
HY-L198
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Alle Vasopressin Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | EC50 |
71 nM
Compound: 3, OVP
|
Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay
Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay
|
[PMID: 21688787] |
| Flp-In-293 | EC50 |
7.5 nM
Compound: 3, OVP
|
Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay
Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay
|
[PMID: 21688787] |
| HEK293 | EC50 |
0.35 nM
Compound: 3, OVP
|
Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 21688787] |
| HEK293 | EC50 |
0.45 nM
Compound: 3, OVP
|
Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay
Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 21688787] |
| HEK293 | EC50 |
0.69 nM
Compound: 3, OVP
|
Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 21688787] |
Chemical Information
-
CAS. Nr. 3397-23-7
-
Appearance Solid
-
Molecular Weight 1042.19
-
Formel C45H63N13O12S2
-
Color White to off-white
-
Synonyms
POR-8
-
Sequence
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-{Orn}-Gly-NH2 (Disulfide bridge: Cys1-Cys6)
-
Sequence Shortening
CYFQNCP-{Orn}-G-NH2 (Disulfide bridge: Cys1-Cys6)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
DMSO : 22.22 mg/mL (21.32 mM; ultrasonic and adjust pH to 3 with 1 M HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (47.98 mM); Clear solution; Need ultrasonic
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. De Kock M, et al. Ornipressin (Por 8): An efficient alternative to counteract hypotension during combined general/epidural anesthesia. Anesth Analg. 2000 Jun;90(6):1301-7. [Content Brief]
[2]. Fruhstorfer H, et al. Dose-response relation of ornipressin with regard to vasoconstriction in human skin. Br J Anaesth. 1994 Aug;73(2):220-4. [Content Brief]
[3]. Kam, P. C., & Tay, T. M. (1998). The pharmacology of ornipressin (POR-8): a local vasoconstrictor used in surgery. European journal of anaesthesiology, 15(2), 133–139. [Content Brief]
[4]. Lenz, K., et al., (1991). Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology, 101(4), 1060–1067. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9595 mL | 4.7976 mL | 9.5952 mL | 23.9879 mL |
| 5 mM | 0.1919 mL | 0.9595 mL | 1.9190 mL | 4.7976 mL | |
| 10 mM | 0.0960 mL | 0.4798 mL | 0.9595 mL | 2.3988 mL | |
| 15 mM | 0.0640 mL | 0.3198 mL | 0.6397 mL | 1.5992 mL | |
| 20 mM | 0.0480 mL | 0.2399 mL | 0.4798 mL | 1.1994 mL |
Ornipressin Related Classifications
HY-P0083 Related Classifications
Powered by Bioz